Article (Scientific journals)
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT.
Kröger, Nicolaus; Sbianchi, Giulia; Sirait, Tiarlan et al.
2021In Leukemia, 35, p. 3551-3580
Peer Reviewed verified by ORBi
 

Files


Full Text
462.pdf
Publisher postprint (1.09 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined. We evaluated the impact of RUX on outcome in 551 myelofibrosis patients who received HSCT without (n = 274) or with (n = 277) RUX pretreatment. The overall leukocyte engraftment on day 45 was 92% and significantly higher in RUX responsive patients than those who had no or lost response to RUX (94% vs. 85%, p = 0.05). The 1-year non-relapse mortality was 22% without significant difference between the arms. In a multivariate analysis (MVA) RUX pretreated patients with ongoing spleen response at transplant had a significantly lower risk of relapse (8.1% vs. 19.1%; p = 0.04)] and better 2-year event-free survival (68.9% vs. 53.7%; p = 0.02) in comparison to patients without RUX pretreatment. For overall survival the only significant factors were age > 58 years (p = 0.03) and HLA mismatch donor (p = 0.001). RUX prior to HSCT did not negatively impact outcome after transplantation and patients with ongoing spleen response at time of transplantation had best outcome.
Disciplines :
Hematology
Author, co-author :
Kröger, Nicolaus
Sbianchi, Giulia
Sirait, Tiarlan
Wolschke, Christine
Beelen, Dietrich
Passweg, Jakob
Robin, Marie
Vrhovac, Radovan
Helbig, Grzegorz
Sockel, Katja
Conneally, Eibhlin
Rubio, Marie Thérèse
Beguin, Yves  ;  Université de Liège - ULiège > Département des sciences cliniques > Hématologie
Finke, Jürgen
Bernasconi, Paolo
Morozova, Elena
Clausen, Johannes
von dem Borne, Peter
Schaap, Nicolaas
Schroyens, Wilfried
Patriarca, Francesca
Di Renzo, Nicola
Yeğin, Zeynep Arzu
Hayden, Patrick
McLornan, Donal
Yakoub-Agha, Ibrahim
More authors (16 more) Less
Language :
English
Title :
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT.
Publication date :
2021
Journal title :
Leukemia
ISSN :
0887-6924
eISSN :
1476-5551
Publisher :
Nature Publishing Group, United Kingdom
Volume :
35
Pages :
3551-3580
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 31 May 2021

Statistics


Number of views
110 (3 by ULiège)
Number of downloads
63 (3 by ULiège)

Scopus citations®
 
33
Scopus citations®
without self-citations
22
OpenCitations
 
18

Bibliography


Similar publications



Contact ORBi